STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 225 participants.

Also called NCT03118518

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 225 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03118518
Other papers using this trial's data
  • Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation The New England journal of medicine, 2021-01-28 DOI, PubMed 33197158

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03118518. Randomized; no masking; primary purpose treatment. Start 2017-06-23 (actual); primary completion 2020-06-25 (actual). Results posted on 2021-08-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation
Acronym
STOP AF First
Condition
Atrial Fibrillation New Onset
Intervention (Device)
Cryoablation
Intervention (Drug)
Antiarrhythmic drug
Lead sponsor
Medtronic Cardiac Ablation Solutions (class: industry)

Record details

Record id
cardio:ct-nct03118518
Content hash
cfd5724781e7fcf714359e2fd13f0a23dfb86bf5ad56b01d94b64fe11e7745e1